James M. Pluda

Phase II Trial of the Antiangiogenic Agent Thalidomide in Patients With Recurrent High-Grade Gliomas

Howard A. Fine, William D. Figg, Kurt A. Jaeckle et al. · Journal of Clinical Oncology · 2000 · 425 citations

In Vivo Activity Against HIV and Favorable Toxicity Profile of 2′,3′-Dideoxyinosine

Robert Yarchoan, Hiroaki Mitsuya, Rose V. Thomas et al. · Science · 1989 · 425 citations

A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.

W D Figg, William Dahut, Paul H. Duray et al. · PubMed · 2001 · 304 citations

Activity of Thalidomide in AIDS-Related Kaposi’s Sarcoma

Richard F. Little, Kathleen M. Wyvill, James M. Pluda et al. · Journal of Clinical Oncology · 2000 · 290 citations

Primary Immunodeficiency, Median Thalidomide Dose, Oncology +12

Phase I Study of Recombinant Human Endostatin in Patients With Advanced Solid Tumors

Roy S. Herbst, Kenneth R. Hess, Hai T. Tran et al. · Journal of Clinical Oncology · 2002 · 277 citations